Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells
Elisa Cappuzzello, Roberta Sommaggio, Paola Zanovello, Antonio Rosato, Elisa Cappuzzello, Roberta Sommaggio, Paola Zanovello, Antonio Rosato
Abstract
Cytokine-Induced killer (CIK) cells are raising growing interest in cellular antitumor therapy, as they can be easily expanded with a straightforward and inexpensive protocol, and are safe requiring only GMP-grade cytokines to obtain very high amounts of cytotoxic cells. CIK cells do not need antigen-specific stimuli to be activated and proliferate, as they recognize and destroy tumor cells in an HLA-independent fashion through the engagement of NKG2D. In several preclinical studies and clinical trials, CIK cells showed a reduced alloreactivity compared to conventional T cells, even when challenged across HLA-barriers; only in a few patients, a mild GVHD occurred after treatment with allogeneic CIK cells. Additionally, their antitumor activity can be redirected and further improved with chimeric antigen receptors, clinical-grade monoclonal antibodies or immune checkpoint inhibitors. The evidence obtained from a growing body of literature support CIK cells as a very promising cell population for adoptive immunotherapy. In this review, all these aspects will be addressed with a particular emphasis on the role of the cytokines involved in CIK cell generation, expansion and functionalization.
Keywords: Adoptive Cell Therapy; Cytokine-Induced Killer cells; Graft-versus-Host disease; Interferon-γ; Interleukin-2; MHC-unrestricted killing.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
Source: PubMed